_1782605483653-86ykd14Q.png)
The most expensive part of your benefits plan may not be your benefits plan.
That sounds backwards, but it is exactly how many Canadian employers get trapped on drug costs. They look at the pooled premium or ASO budget, see a painful renewal, and negotiate around the edges. A few percentage points here. A deductible tweak there. Maybe a tighter annual maximum.
Meanwhile, the real cost driver is often sitting in a tiny number of claims: specialty drugs.
If you have 100 to 1,000 employees, you do not need a huge population to feel this. One claimant on a high-cost biologic, infusion therapy, or rare-disease medication can change the conversation quickly. And yet many employers still govern these claims as though they are simply “drugs, but pricier.”
They are not.
Specialty drugs are not a utilization problem
Traditional drug plans were built around frequency: lots of common claims, relatively predictable patterns, broad access through retail pharmacies, and plan design levers like co-insurance or dispensing fee limits.
Specialty drugs break that model.
They tend to involve:
- very high annual cost per claimant
- complex clinical conditions
- manufacturer support programs
- prior authorization requirements
- site-of-care decisions
- adherence and case management issues
- opportunities for biosimilar switching or managed formularies
That means the main question is no longer, “How much drug usage do we have?”
It is, “How well are these claims being managed from the moment they appear?”
The provocative truth: many employers are overpaying not because they are too generous, but because they are too passive.
A passive plan waits for a claim to happen and then funds it. A managed plan asks whether the member is on the right therapy, sourced the right way, with the right support, under the right funding structure.
That is not denial. It is stewardship.
Why this matters more in the mid-market than you think
Large national employers often have the scale, reporting, and internal expertise to pressure carriers on specialty management. Smaller employers may be fully pooled and somewhat insulated, at least in the short term.
Mid-market employers are in the most awkward spot.
You are big enough to experience volatility, but often not big enough to have a formal strategy behind it. Your HR team is busy. Your CFO sees costs rising. Your advisor may talk about pooling, but not about the claim pathway itself.
So the organization ends up paying for volatility without controlling the machinery behind it.
In Canada, the details vary by carrier and funding arrangement, whether you are with Sun Life, Canada Life, Manulife, or another insurer. But the strategic issue is the same: if specialty governance is weak, your renewal story is being written long before your renewal meeting.
What a carve-out mindset actually means
“Carve-out” does not always mean ripping your drug plan away from the carrier and rebuilding it from scratch. Sometimes it does. Often, it starts with a simpler shift: isolating specialty management as its own strategic workstream.
That can include one or more of the following:
- a separate review of high-cost drug oversight
- tighter prior authorization protocols
- biosimilar-first rules where clinically appropriate
- preferred pharmacy or specialty pharmacy networks
- infusion or injection site-of-care optimization
- more rigorous manufacturer assistance coordination
- clearer pooling and stop-loss analysis under your funding model
- independent review of whether your current carrier arrangement is competitive
The key is that specialty claims should not be buried inside a general renewal discussion.
If your broker shows you a total drug trend number but cannot explain how high-cost claimants are being clinically and operationally managed, you do not have a strategy. You have a summary.
Three questions employers should be asking right now
1) Who owns the specialty claim pathway?
Not in theory. In practice.
When a member is prescribed a specialty medication, who ensures:
- the claim is adjudicated appropriately
- prior authorization criteria are met
- a biosimilar is considered where applicable
- the member is connected to manufacturer support
- the dispensing channel is cost-effective
- adherence issues are managed before waste occurs
If the answer is vague, fragmented, or “the carrier handles that,” ask for specifics.
A sophisticated carrier may have strong capabilities. But employers should still know what happens behind the curtain.
2) Are we using plan design levers that actually work for specialty drugs?
Many common cost-sharing tools are blunt instruments here.
A higher deductible does little against a six-figure annual therapy. Co-insurance may simply create affordability stress for the employee until the carrier support program intervenes, or until the plan maximum is hit. Neither outcome reflects a thoughtful benefits strategy.
More effective levers are often clinical and structural, not cosmetic:
- evidence-based authorization
- mandatory biosimilar protocols where appropriate
- specialty pharmacy management
- case management integration
- coordination with provincial programs where available
Canadian employers also need to stay aware of the interaction between private coverage and public systems. Depending on the province, age, income, diagnosis, or drug category, there may be provincial drug support programs in play. The right approach is not to offload blindly, but to coordinate properly and compliantly.
3) Does our funding structure match our risk reality?
This is where finance leaders should lean in.
If you are on ASO or refund accounting, specialty exposure may be showing up more directly in your experience. If you are fully insured, pooling protection may help, but it does not make the underlying trend irrelevant. Pooling charges still rise when the market sees more high-cost claims.
So the question is not simply whether you are protected this year. It is whether your current arrangement is still the best fit for:
- your cash flow tolerance
- your claims volatility
- your employee demographics
- your appetite for plan control
- your ability to govern high-cost claims over time
Too many employers discuss funding as a technical insurance choice. It is really a business-risk choice.
The cultural mistake employers make
There is also a people issue here.
When specialty management is framed poorly, leaders worry that any intervention will feel harsh or anti-employee. So they avoid the topic until costs force a reactive change.
That is the wrong sequence.
A well-managed specialty strategy can actually improve the member experience. Employees dealing with serious conditions do not just need reimbursement. They need navigation, clinical support, coordination, and fewer administrative gaps.
The goal is not to pay less by making access harder.
The goal is to pay smarter while making high-need cases work better.
That is a much stronger message to employees, managers, and boards alike.
What to do before your next renewal cycle
If this area has been treated as background noise, start with a focused review:
- identify how many high-cost claimants are driving drug spend
- map the current specialty drug process with your carrier or advisor
- review biosimilar, prior authorization, and specialty pharmacy rules
- assess manufacturer assistance coordination
- evaluate whether your funding model still makes sense
- ask for a specialty-specific strategy, not just a renewal forecast
You do not need to wait for a crisis claim to do this work. In fact, that is the most expensive time to start.
The employers that handle specialty costs best are rarely the ones with the stingiest plans. They are the ones with the clearest rules, the best data, and the discipline to treat high-cost drugs as a governed category.
That is where the market is heading. As specialty therapies continue to grow, the winners will not be the employers who bargain hardest on premium. They will be the ones who finally realize their drug plan is not just insurance. It is a managed healthcare purchasing strategy.
And that shift in mindset will matter a lot more than the next one-point concession at renewal.
